Stay updated with breaking news from Sam Kintz. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Enliven Therapeutics Inc. (Nasdaq: ELVN), a Boulder clinical-stage precision oncology company, has enough cash on hand to fund operations into late 2026, the company disclosed this week, and through multiple milestones for two of its drug candidates.
Achieved initial cumulative MMR rate of 44% by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of approved BCR::ABL1 TKIs Achieved initial cumulative...
Achieved initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients, which compares favorably to precedent Phase 1 trials of...
BOULDER, Colo., April 09, 2024 (GLOBE NEWSWIRE) -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage precisio...
Enliven Therapeutics Inc. roughly doubled its year-over-year net losses as advances in its drug-development pipeline have resulted in increased research and development costs.